Enlivex Therapeutics (NASDAQ:ENLV) Receives Buy Rating from D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock.

A number of other equities analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Enlivex Therapeutics in a research report on Friday, September 27th. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 27th.

Enlivex Therapeutics Stock Performance

NASDAQ ENLV opened at $1.27 on Wednesday. Enlivex Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.59. The company has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $1.35. The company has a market capitalization of $27.08 million, a PE ratio of -1.32 and a beta of 1.01.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in shares of Enlivex Therapeutics during the second quarter worth approximately $35,000. Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics in the third quarter worth $50,000. Finally, Armistice Capital LLC purchased a new position in shares of Enlivex Therapeutics in the second quarter worth $2,415,000. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.